| Serial Number | 98105723 |
| Word Mark | CAR-PLT |
| Filing Date | Thursday, July 27, 2023 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Monday, October 27, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 29, 2025 |
| Goods and Services | Testing and analysis of blood plasma, red blood cells, white blood cells, blood platelets for scientific research purposes |
| Goods and Services | Platelet-rich plasma therapy; blood banks |
| Goods and Services | Medicinal infusions for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drugs for medical purposes, namely, pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Therapeutic drugs and agents, namely, pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drug delivery agents in the form of infusion bags filled with platelets, infusion bags filled with platelets in suspension ready for infusion, infusion bags filled with lyophilized platelets, infusion bags filled with lyophilized platelets to be resuspended before infusion, infusion bags filled with cryopreserved platelets, infusion bags filled with cryopreserved platelets to be thawed prior to infusion that facilitate the delivery of proteins, peptides, long and short RNA, siRNA, miRNA, and saRNA; Drug delivery agents in the form of infusion bags filled with platelets, infusion bags filled with platelets in suspension ready for infusion, infusion bags filled with lyophilized platelets, infusion bags filled with lyophilized platelets to be resuspended before infusion, infusion bags filled with cryopreserved platelets, infusion bags filled with cryopreserved platelets to be thawed prior to infusion consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Medicines for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Pre-filled syringes and infusion bags for medical purposes featuring pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drug delivery agents infused in a patient's blood consisting of compounds that facilitate delivery of a wide range of pharmaceuticals |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, August 28, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, August 28, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, August 28, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | HemostOD SA |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Saint-Sulpice 1025 CH |
| Party Name | HemostOD SA |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Saint-Sulpice 1025 CH |
| Event Date | Event Description |
| Monday, July 31, 2023 | NEW APPLICATION ENTERED |
| Monday, August 28, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, August 21, 2023 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Friday, January 12, 2024 | ASSIGNED TO LIE |
| Friday, January 12, 2024 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Thursday, March 28, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, April 17, 2024 | NON-FINAL ACTION WRITTEN |
| Wednesday, April 17, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, April 17, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, July 16, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, July 16, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, July 16, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, January 17, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, January 17, 2025 | NON-FINAL ACTION E-MAILED |
| Friday, January 17, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, March 31, 2025 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, March 31, 2025 | EXAMINERS AMENDMENT E-MAILED |
| Monday, March 31, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, March 31, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, April 1, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 23, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, April 29, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, April 29, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 24, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, October 27, 2025 | SOU TEAS EXTENSION RECEIVED |
| Monday, October 27, 2025 | SOU EXTENSION 1 FILED |
| Monday, October 27, 2025 | SOU EXTENSION 1 GRANTED |
| Tuesday, October 28, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |